Cytokinetics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Cytokinetics reported Q3 2026 total revenue of $47.6 million, compared with $1.9 million in the same period in 2025.
- MyCorzo net product revenue was $44.5 million, up 76% quarter over quarter; U.S. revenue was $43.1 million and Europe contributed $1.4 million.
- Nearly 1,100 unique U.S. healthcare providers had prescribed MyCorzo by the end of Q3, and it had been dispensed to more than 2,800 patients, up approximately 86% from 1,500 at the end of Q2.
- Management said MyCorzo’s new-to-brand exit share in the CMI category was approaching 45% in Q3, up from approximately 40% in Q2, and reaffirmed its goal of greater than 50% by year-end.
- The CMI market grew 56% in new-to-brand prescriptions in Q3 '26 versus Q3 '25; management said the market had grown 45% year to date since MyCorzo’s introduction.
- R&D expenses were $99.3 million, compared with $97.3 million in the same period in 2025, and SG&A expenses were $113.1 million, compared with $69.5 million.
- Net loss was $190.1 million, or $1.37 per share, compared with a net loss of $306.2 million, or $2.55 per share, in the same period in 2025.
- Cytokinetics ended Q3 with approximately $1.6 billion in cash and investments, compared with $1.7 billion at the end of Q2 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for standing by, and welcome to the Cytokinetics Q3 2026 earnings call. This call is being recorded, and all participants are in a listen-only mode. After the speaker's remarks, we will open the call to questions. We will allow for one question per participant. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Affairs.
Please go ahead. Good afternoon, and thanks for joining us on the call today.
The slides accompanying today's webcast can be found on the Investors and Media section of our website at cytokinetics.com, along with today's press release. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Andrew Callos, EVP and Chief Commercial Officer, will discuss the commercial launch of MYQORZO in the U.S. and Europe. Fady Malik, EVP of R&D, will provide updates related to aficamten. Steve Heitner, SVP and Chief Medical Officer, will provide updates related to our ongoing clinical development programs. Sung Lee, EVP and Chief Financial Officer, will provide a financial overview for the quarter. Finally, Robert will make closing remarks. As you can see on this slide, today's discussion will include forward-looking statements, which are subject to risks and uncertainties.
Please refer to our SEC filings for a discussion of these factors. Now, I will turn the call over to Robert.
Thank you, Diane, and thanks to all for joining us on the call today. The third quarter was another period of strong execution for Cytokinetics as we continue to build a leading muscle-focused specialty cardiology company. In Q3, we made progress on each of our priorities underlying that strategy. Nearly nine months in, the launch of MYQORZO continues to exceed our expectations. In the third quarter, MYQORZO generated $44.5 million in net revenue, up 76% from Q2. As Andrew will describe, the number of prescribers, prescribing per physician, and patients dispensed all increased. We believe these trends reflect the differentiated profile of MYQORZO, and we see significant room for continued growth. Outside the United States, our launch in Germany is off to a strong start, and we continue to secure approvals in additional geographies, including recently in Canada and the United Kingdom.
We expect to launch in the U.K. this quarter and in additional countries in 2027. We're also looking forward to the PDUFA date for data relating to MAPLE-HCM, which is November 14. Beyond oHCM, we're working diligently to bring aficamten to more patients living with HCM. in August, we presented the full results from ACACIA-HCM in a hotline session at ESC, with simultaneous publication in the New England Journal of Medicine. In fact, the presentation was included in the opening plenary session for ESC, a clear sign of enthusiasm from the cardiology community, which today has no approved therapy that addresses the underlying disease for nHCM. We also presented additional results at ESC from pre-specified analyses from ACACIA-HCM that further underscore the potential of aficamten in nHCM. These results bring us closer to the potential commercial availability of a treatment for the full spectrum of symptomatic HCM patients.
Based on these results, we're on track to submit a supplemental NDA to FDA this quarter and an application to the EMA in early 2027. At the same time, pending regulatory approval, we're preparing for the potential launch in nHCM, building on the commercial foundation we've established with MYQORZO in oHCM. Andrew will share more on our commercial readiness in a moment. Beyond aficamten, we continue to advance our pipeline during the quarter. Our later-stage clinical trials for omecamtiv mecarbil and ulacamten continue to make progress. Earlier in our pipeline, we achieved a preclinical milestone in our collaboration with Accutar, which is focused on targeted protein degraders for muscle-related diseases. Taken all together, our third-quarter results demonstrate the progress we're making towards our Vision 2030.
Looking ahead, our priorities are clear: submit the sNDA in nHCM, prepare for a potential nHCM launch, expand MYQORZO into additional geographies, and importantly, continue our commercial momentum in oHCM while advancing our pipeline, all while staying disciplined to how we deploy capital. With that, I'll now turn the call over to Andrew, please.
Thank you, Robert. MYQORZO delivered another quarter of strong growth, and the launch continues to exceed our expectations. In Q3, we are pleased to see growth across prescribing, patient demand, and market access, all while the CMI category itself continued to expand. These trends show that MYQORZO is on a strong trajectory in the first year. We're focused on building that momentum into 2027. As we committed at launch, we continue to measure performance using three key metrics: breadth of prescribing, depth of prescribing, and patient volume. In the third quarter, we saw continued growth across all three, driven by an expanding prescriber base. By the end of the third quarter, nearly 1,100 unique healthcare providers in the U.S. had prescribed MYQORZO, up from more than 700 at the end of Q2.
On average, these HCPs have prescribed MYQORZO to nearly four of their patients, up from three last quarter. Among high-volume CMI writers, the figure is seven patients, up from five in the second quarter. We believe this increase in prescribing reflects growing physician confidence in MYQORZO. Turning to patient demand, by the end of the third quarter, MYQORZO had been dispensed to more than 2,800 patients, up approximately 86% from 1,500 at the end of Q2. While syndicated data has limitations, our internal analysis suggests that new-to-brand exit share for MYQORZO in the CMI category is continuing to grow and approaching 45% in the third quarter, up from approximately 40% in the second quarter. Our launch strategy was to focus on high-volume CMI prescribers, and our NBRx share is highest among these HCPs, approaching 50%, a leading indicator of future growth.
We remain committed to our goal of achieving greater than 50% new-to-brand exit share by year-end, which would represent a strong result for the second entrant in less than a year of launch. Beyond capturing new-to-brand share, MYQORZO is also helping to expand the CMI category. Q3 2026 versus Q3 2025 new-to-brand prescription grew 56%. When comparing year-to-date growth for the same period in 2025, the CMI market has grown 45% since the introduction of MYQORZO, and there is still significant room to grow. Of approximately 120,000 eligible oHCM patients in the U.S., only about 28,000 are treated with a CMI today. That leaves over 75% of CMI-eligible patients who could benefit from therapy, and that's where our launch continues to be focused. As we said prior to our launch, prescribing was concentrated among high-volume CMI prescribers who historically accounted for approximately 80% of CMI volume.
By the end of Q3, our sales team had reached more than 95% of these HCPs. Since launch, as we've continued to grow share among high-volume prescribers, adoption has also broadened beyond this core group. Specifically, low-volume CMI prescribers now represent 30% of all MYQORZO prescribers, while prescribers naive to CMI represents another 35%. Importantly, in Q3, we estimate that the CMI-naive prescriber segment accounted for approximately 70% of total CMI growth since Q2. We continue to expand access and ended the third quarter with over 60% of commercial lives covered, up from 50% of lives covered at the end of Q2, while continuing to maintain a consistent level of Medicare coverage throughout 2026. In Q3, we continued to achieve over 80% of paid prescriptions, showing continued success in access and our ability to manage payer appeal process.
Outside the United States, our launch in Germany is continuing to gain traction. By the end of August, MYQORZO had already captured more than 50% of new CMI patient starts. We also recently received approval in Canada, and we expect to launch in the U.K. this quarter and in additional countries in 2027. As a result, we expect MYQORZO to be available in all key European markets in 2027. At the same time, as we move towards our planned sNDA submission for nHCM this quarter, we're preparing for a potential commercial launch in that indication in 2027. Our field force was designed from the start to reach the physicians who treat both obstructive and non-obstructive patients, so the infrastructure is already in place.
We're also building disease awareness through unbranded education, and our payer account teams are preparing to engage payers in compliant preapproval information exchange in preparation for coverage discussions. In the U.S., we estimate that over 200,000 patients have been diagnosed with nHCM, and over 120,000 are symptomatic and eligible for treatment. Recent market research reacting to ACACIA-HCM suggests that if MYQORZO is approved for the treatment of symptomatic patients with nHCM, physicians see a meaningful role for their therapy, particularly among patients with greater symptom burden or persistent functional limitations, where unmet need is highest. Importantly, physicians indicated that patients with the greatest symptom burden may be the most likely to receive treatment, potentially driving higher utilization within this segment. Moreover, a dual indication label could further strengthen MYQORZO's position in oHCM, as physicians gain broader experience and confidence with MYQORZO across both obstructive and non-obstructive HCM.
Ultimately, we hope MYQORZO will be approved to address this important unmet need. Overall, we are very encouraged by the performance in our launch markets. It reflects a differentiated profile of MYQORZO and the execution of our colleagues across the U.S. and Europe. Together, this progress is building a strong foundation for continued growth. With that, I'll turn the call over to Fady.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
25 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
